Complement Pathway Inhibitor Compounds With Selective C1 Esterase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for pharmaceutically acceptable compounds to inhibit the complement system, particularly the C1 esterase, to treat disorders mediated by its dysfunction, including inflammatory and immune conditions, and to prevent undesired complement-mediated responses to medical treatments or procedures.
Innovation Solution
Development of compounds of specific formulas (I through XX) and their pharmaceutically acceptable salts, prodrugs, isotopic analogs, or isolated isomers, which act as inhibitors of the complement classical pathway, alternative pathway, or lectin pathway, or a combination thereof, to treat disorders associated with these pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are developed to inhibit the complement system, then treatment effectiveness for complement-mediated disorders is improved, but risk of infections increases due to reduced immune defense
Solution Approach 1:
The patent applies local quality by designing compounds that selectively inhibit specific complement pathways (classical, alternative, or lectin) rather than broadly suppressing the entire complement system. This selective inhibition allows treatment of specific complement-mediated disorders while preserving other immune defense mechanisms, thus reducing infection risk compared to broad-spectrum complement inhibition
Solution Approach 2:
The patent employs parameter changes by developing compounds with varying degrees of complement inhibition strength and specificity. By adjusting the inhibition parameters of different compound formulations, the treatment can be optimized to achieve therapeutic effectiveness for specific disorders while maintaining sufficient complement activity to protect against infections
2Adaptability or versatility
If broad-spectrum complement inhibition is used, then treatment coverage for various complement-mediated disorders is improved, but specificity of action decreases leading to off-target effects
Solution Approach 1:
The patent applies segmentation by dividing complement inhibition into separate pathway-specific compounds. Instead of using a single broad-spectrum inhibitor, the patent develops distinct compounds targeting the classical pathway, alternative pathway, and lectin pathway separately, allowing precise selection of the appropriate compound based on the specific disorder and pathway involvement
3Reliability
If high doses of complement inhibitors are administered, then therapeutic effect is improved, but side effects increase due to excessive immune suppression
Solution Approach 1:
The patent employs intermediary principles by developing compounds with optimized pharmacokinetic properties that allow sustained therapeutic effects at lower doses. The compounds are designed to maintain stable plasma concentrations and prolonged half-life, reducing the need for high dosing frequencies and minimizing cumulative immune suppression that leads to side effects
Data Source
AI summary
This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl-mediated disorders.